About this study
SJATRT is a clinical trial studying more effective treaatments for a rare and fast-growing cancerous tumor called malignant rhabdoid tumor (MRT). MRTs are types of tumors that are found in the brain, and/or in other areas of the body, particularly the kidneys, but also liver and other soft tissue sites. When an MRT originates in the brain or spinal cord, it is usually called an atypical teratoid rhabdoid tumor (ATRT).
MRTs and ATRTs can be difficult to cure. Children with MRTs and ATRTs are usually treated with surgery, radiation therapy and chemotherapy drugs.
Treatment on this research study is based on a “risk-adapted” approach. Children taking part in this study will be divided into different risk groups. The risk group your child will be assigned to depends on certain aspects of your child’s tumor, such as age at diagnosis and whether or not the tumor has spread to the spinal fluid and/or other areas of the brain and spine.
Treatment
There are three parts to this study:
- Staging–The first step is to determine how much tumor is present and where it has spread.
- Treatment – Treatment depends on several key factors, including if the tumor is recurrent/progressive or newly diagnosed, your child’s age and clinical risk. All participants enrolled in this study will be treated with alisertib. Some participants may also receive treatment with surgery, chemotherapy and radiation.
- Follow-up – After treatment ends, routine follow-up examinations and medical tests will be done for about five years following treatment.
Eligibility overview
- Has one of the following:
- Newly diagnosed atypical teratoid rhabdoid tumors (ATRTs) with or without tumors affecting other areas outside the brain and spine
- ATRTs or malignant rhabdoid tumors (MRTs) that have come back after initial treatment (recurrent/progressive disease)
- 21 years of age or younger